VOGX (Vogenx) EV-to-OCF: (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vogenx's Enterprise Value is $196.52 Mil. Vogenx does not have enough years/quarters to calculate its Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's EV-to-OCF at this moment.

The historical rank and industry rank for Vogenx's EV-to-OCF or its related term are showing as below:

VOGX' s EV-to-OCF Range Over the Past 10 Years
Min: -176.72   Med: 0   Max: 0
Current: -176.72
VOGX's EV-to-OCF is ranked better than
97.45% of 1410 companies
in the Biotechnology industry
Industry Median: -3.52 vs VOGX: -176.72

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-14), Vogenx's stock price is $14.09. Vogenx does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Vogenx's PE Ratio (TTM) at this moment.

Vogenx  (NAS:VOGX) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Vogenx's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.09/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Vogenx EV-to-OCF Related Terms

Vogenx EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Vogenx's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx EV-to-OCF Chart

Vogenx Annual Data
Trend Dec24 Dec25
EV-to-OCF
0.00 0.00

Vogenx Semi-Annual Data
Dec24 Dec25
EV-to-OCF 0.00 0.00

VOGX vs : EV-to-OCF Comparison

For the Biotechnology subindustry, Vogenx's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vogenx EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vogenx's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Vogenx's EV-to-OCF falls into.


VOGX
8GF Score
Vogenx Inc VOGX
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx EV-to-OCF Calculation

Vogenx's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=196.516/
=

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price